GRI Bio, Inc. (NASDAQ:GRI) Short Interest Update

GRI Bio, Inc. (NASDAQ:GRI) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 438,400 shares, a growth of 15,557.1% from the August 15th total of 2,800 shares. Based on an average daily volume of 602,900 shares, the short-interest ratio is currently 0.7 days. Currently, 15.0% of the shares of the company are short sold.

GRI Bio Trading Down 0.4 %

GRI Bio stock opened at 0.50 on Friday. GRI Bio has a 52 week low of 0.40 and a 52 week high of 161.98. The business’s 50-day simple moving average is 0.86 and its 200-day simple moving average is 4.32.

GRI Bio (NASDAQ:GRI) last released its quarterly earnings results on Tuesday, August 13th. The company reported -4.92 earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GRI Bio stock. Armistice Capital LLC bought a new position in shares of GRI Bio, Inc. (NASDAQ:GRI) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 50,207 shares of the company’s stock, valued at approximately $96,000. Armistice Capital LLC owned 9.23% of GRI Bio at the end of the most recent quarter. Institutional investors and hedge funds own 33.95% of the company’s stock.

About GRI Bio

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.